A new tablet, orforglipron, helped people with type 2 diabetes lose up to 8% of body weight.
The drug acts on GLP-1 receptors, lowers blood sugar, and reduces appetite.
Patients can take it without fasting.
In a year-long phase 3 trial, it outperformed oral semaglutide for weight loss and glucose control.
More participants stopped treatment because of gastrointestinal side effects.
Regulators have not yet approved the pill.
Experts see major potential for easier, cheaper therapy without injections.
They still need long-term safety and cardiovascular data.
